AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 153 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $99,000 | +106.2% | 2,879 | 0.0% | 0.00% | – |
| Q2 2020 | $48,000 | +14.3% | 2,879 | 0.0% | 0.00% | – |
| Q1 2020 | $42,000 | -56.2% | 2,879 | 0.0% | 0.00% | – |
| Q4 2019 | $96,000 | -15.0% | 2,879 | -46.9% | 0.00% | – |
| Q2 2019 | $113,000 | -6.6% | 5,426 | 0.0% | 0.00% | – |
| Q1 2019 | $121,000 | +59.2% | 5,426 | +63.7% | 0.00% | – |
| Q4 2018 | $76,000 | -16.5% | 3,315 | 0.0% | 0.00% | – |
| Q3 2018 | $91,000 | +2.2% | 3,315 | 0.0% | 0.00% | – |
| Q2 2018 | $89,000 | -16.0% | 3,315 | 0.0% | 0.00% | – |
| Q1 2018 | $106,000 | -15.2% | 3,315 | 0.0% | 0.00% | – |
| Q4 2017 | $125,000 | +54.3% | 3,315 | 0.0% | 0.00% | – |
| Q3 2017 | $81,000 | +19.1% | 3,315 | 0.0% | 0.00% | – |
| Q2 2017 | $68,000 | -5.6% | 3,315 | 0.0% | 0.00% | – |
| Q1 2017 | $72,000 | +5.9% | 3,315 | 0.0% | 0.00% | – |
| Q4 2016 | $68,000 | – | 3,315 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital LLC | 1,240,000 | $25,966,000 | 57.34% |
| Foresite Capital Management II, LLC | 2,605,499 | $54,559,000 | 11.53% |
| Foresite Capital Management III, LLC | 611,893 | $12,813,000 | 4.89% |
| Palo Alto Investors LP | 3,471,740 | $72,698,000 | 4.84% |
| SANDERS MORRIS HARRIS LLC | 486,906 | $10,196,000 | 2.47% |
| Eventide Asset Management | 3,084,000 | $64,579,000 | 2.13% |
| Sofinnova Investments, Inc. | 346,770 | $7,261,000 | 0.66% |
| EMERALD ADVISERS, LLC | 610,511 | $12,784,000 | 0.60% |
| RICE HALL JAMES & ASSOCIATES, LLC | 752,358 | $15,754,000 | 0.56% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 587,464 | $12,301,000 | 0.54% |